EPISODE · Jul 14, 2025 · 21 MIN
Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments
from WTR Healthcare Happenings · host Joe Brunetto
In our first rebranded WTR Healthcare Spotlight, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that highlight advantages that distinguish Cybin's lead program CYB003 from other aspiring late-stage novel therapies in the depression treatment landscapeCybin (NYSE: CYBN) is a late-stage clinical development company focused on developing novel psychedelic-based neuropsychiatric compounds. Its two lead candidates, targeting two of the most pervasive mental health disorders, are psilocin-based CYB003 for Major Depressive Disorder (MDD), currently being dosed in a Phase 3 program, and DMT-based CYB004 for General Anxiety Disorder (GAD) which is wrapping up a Phase 2 study.
What this episode covers
In our first rebranded WTR Healthcare Spotlight, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that highlight advantages that distinguish Cybin's lead program CYB003 from other aspiring late-stage novel therapies in the depression treatment landscape Cybin (NYSE: CYBN) is a late-stage clinical deve...
NOW PLAYING
Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments
No transcript for this episode yet
Similar Episodes
No similar episodes found.